PDCD1 and nasopharyngeal carcinoma: Becotatug vedotin achieved an ORR of 30.2% in R/M NPC patients who had received prior platinum chemo and anti-PD-1/PD-L1 therapy, compared to that of 11.2% with standard chemotherapy [84].